Indaptus Therapeutics Completes Leadership Transition with Key Board and COO Resignations
INDP has more than doubled off its 52-week low of $0.92 on elevated volume (3.4× avg).
Summary
Indaptus Therapeutics announced the resignations of two directors, including former co-CEO David E. Lazar, and its Chief Operating Officer, finalizing the leadership transition initiated by new investors.
Key Events · Executive and Board Changes · INDP
-
Two Directors Resign
David E. Lazar and Avraham Ben-Tzvi resigned from all directorship positions, effective June 5, 2026. Lazar was previously involved in a significant preferred stock disposition during the change of control.
-
Chief Operating Officer Departs
Walt A. Linscott, Esq. resigned as COO, effective June 1, 2026, but will continue to serve the company as a consultant.
-
Formalizes Leadership Transition
These departures complete the leadership restructuring following the change of control and appointment of new management and directors in March and April, aiming to stabilize the financially distressed company.
Analysis · INDP · Life Sciences
This 8-K formalizes the departure of two directors, David E. Lazar and Avraham Ben-Tzvi, and Chief Operating Officer Walt A. Linscott. These resignations complete the leadership overhaul following the significant change of control and new investor group that took over in March and April. While resignations can be negative, in this context, they represent the final step in establishing the new management team and board to address the company's severe financial challenges and halted clinical programs.
At the time of this filing, INDP was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $414.5M. The 52-week trading range was $0.92 to $19.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.